Navigating the CGT Frontier: Seamlessly Transitioning From Development to Commercial Manufacturing

The cell and gene therapy (CGT) industry is transforming lives and growing fast. With projections showing a $177.46 billion market by 2034 and an 18.7% CAGR¹, the potential is incredible. But here's the reality check: current manufacturing capacity meets only 5%-10% of what's needed to scale these life-changing therapies.

Bridging Lab Success to Commercial Reality

CGT products don't just treat conditions. They transform lives. But bringing these breakthrough therapies from lab to patient requires more than great science. It demands smart manufacturing strategy.

The journey from research to commercial scale doesn't have to be overwhelming. With the right approach, you can navigate these challenges while staying focused on what matters most: getting revolutionary treatments to the patients who need them, and delivering them as quickly as possible.

Want a roadmap for your CGT commercialization journey? Download "The Ultimate Guide to Digitizing Cell and Gene Therapy Manufacturing" to get started.

3 Game-Changing Strategies for CGT Success

Strategy 1: Standardize Without Compromise

Your therapies are unique, so your manufacturing approach should be too. That means your processes should be built on flexible platforms with modular components that can adapt to your specific needs. This approach lets you:

• Produce diverse or individualized therapies while maintaining consistent quality.
• Reduce variability from day one.
• Achieve right-first-time production.
• Save time and resources.

When standardization meets flexibility, you can scale without sacrificing what makes your therapy special.

Strategy 2: Go Digital, Get Results

Paper-based processes? In this industry? Not anymore.

Digital solutions transform how you manage production records, work instructions, and quality assurance. Companies using modern manufacturing execution solutions like MasterControl Manufacturing Excellence (Mx) are seeing:

• Review cycles shortened from days to hours.
• Drastically reduced errors and deviations.
• Faster product release through "review by exception."
• Lower costs that make therapies more accessible to patients.

When you digitize your CGT operations, you're not just improving efficiency—you're creating more opportunities to change lives.

Ready to transform your CGT manufacturing processes? Our Ultimate Guide to Digitizing Cell and Gene Therapy Manufacturing shows you exactly how.

Strategy 3: Connect Everything (and Everyone)

Breakthrough innovation requires collaboration. Integrated systems connect your production activities with enterprise systems like enterprise resource planning (ERP) systems, manufacturing execution systems (MES), and quality management systems (QMS) for real-time data sharing that eliminates reconciliation headaches.

MasterControl's ADAPT Platform brings quality, manufacturing, and asset management together in one place—giving you complete visibility and control over your operations. When everything connects, you can focus on innovation instead of information gaps.

Overcoming the Roadblocks

CGT manufacturing comes with challenges such as:

• Data integrity concerns: Digital solutions maintain pristine data trails that stand up to regulatory scrutiny.
• Regulatory complexity: Efficient processes and robust data management support faster approvals.
• Scaling hurdles: Standardized, digital processes let you meet growing demand without compromising quality.

Looking for industry-proven solutions to these common CGT challenges? Download our comprehensive guide on digitizing CGT manufacturing for expert insights.

Your Partner on the CGT Journey

For decades, we've helped life sciences companies modernize operations and maintain compliance. Our comprehensive solutions aren't just about solving today's challenges—they're about future-proofing your operations for whatever comes next in the evolving CGT landscape.

Ready to Transform CGT Manufacturing?

The path from breakthrough discovery to life-changing therapy shouldn't be blocked by manufacturing limitations. By embracing standardization, digitalization, and integration, you can overcome industry challenges and get innovative treatments to patients faster.

That changes everything.

Want to learn more? Download our guide: The Ultimate Guide to Digitizing Cell and Gene Therapy Manufacturing.

References:

1. "The Ultimate Guide to Digitizing Cell and Gene Therapy Manufacturing," MasterControl, 2025.